REPLIGEN CORPORATION ($NASDAQ:RGEN) reported total revenue of USD 159.2 million for the quarter ending June 30 2023, a decrease of 23.3% from the same period the prior fiscal year. Furthermore, net income for the second quarter decreased by 59.8%, amounting to USD 20.1 million.
GoodWhale recently conducted an extensive analysis of REPLIGEN CORPORATION‘s wellbeing. According to Risk Rating, REPLIGEN CORPORATION is a high risk investment in terms of financial and business aspects. GoodWhale has detected 3 risk warnings in the company’s income sheet, balance sheet, and cashflow statement. They have identified potential risks that could lead to a loss of funds for investors. To help protect potential investors from financial losses, GoodWhale has made all of their findings and research available on their website. Those interested in REPLIGEN CORPORATION’s financial performance can easily register on goodwhale.com to check it out. GoodWhale provides comprehensive analyses of companies of all sizes and sectors, making it an invaluable resource for investors and other stakeholders. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Repligen Corporation. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Repligen Corporation. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Repligen Corporation. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Repligen Corporation are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
The company’s products include proteins and antibodies for the treatment of cancer, central nervous system disorders, and infectious diseases. ReGen Biologics Inc, Tecan Group AG, Stevanato Group SPA are all competitors in the market for developing and commercializing therapeutics.
Regen Biologics, Inc. is a biotechnology company, which focuses on the development, commercialization, and marketing of products in the orthopedic regenerative medicine field. The company’s products include collagen-based scaffolds for use in orthopedic and sports medicine indications. It operates in the United States, Europe, and Asia. The company was founded by David A. Jay and Stephen J. Sacks in 1997 and is headquartered in Laguna Niguel, CA.
Tecan Group AG is a Swiss-based manufacturer of laboratory instruments and solutions for the life sciences sector. The company has a market cap of 4.54B as of December 2020 and a Return on Equity of 6.13%. Tecan Group AG’s products are used in academic and commercial research laboratories, as well as in clinical diagnostic laboratories. The company’s instruments are used for a variety of applications, including drug discovery and development, biopharmaceutical production, food safety testing, and environmental monitoring.
– Stevanato Group SPA ($NYSE:STVN)
Stevanato Group is a leading provider of integrated solutions for the pharmaceutical and biotech industry. The Group offers a complete range of services, from design and development to manufacturing and packaging of finished products. The Group’s products are used in a wide range of therapeutic areas, including cancer, immunology, infectious diseases and neurology.
Investors should be wary of REPLIGEN CORPORATION as the company reported a significant decrease in revenue and net income for the quarter ending June 30 2023. Total revenue for the quarter was USD 159.2 million, a decrease of 23.3% compared to the same period in the previous fiscal year. Net income was USD 20.1 million, a decrease of 59.8%. Therefore, investors should take caution when considering investing in REPLIGEN CORPORATION as it may not be a viable or profitable investment option.